Received: 30 August 2022
Accepted: 26 December 2022
First Online: 27 January 2023
: All relevant Institutional Review Board/Independent Ethics Committee approvals were gained before commencement of the study, and are listed in the supplementary information (Supplementary Table InternalRef removed). The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki. All patients gave written informed consent before participation.
: Not applicable.
: The PRECONNECT study was funded by Institut de Recherches Internationales, Servier, France; JT has received honoraria for speaker or advisory role from Servier, Roche, Lilly, Celgene, Shire, Amgen, Sanofi, Merck, Lilly and Sirtex; TP has received compensation for advisory board for Amgen (paid self), Merck, Roche and Takeda (paid self); LV and BC are employees of Servier; LW has received honoraria for consulting or advisory roles from Servier, and Halozyme, has served on a Speakers Bureau for Amgen and holds patents, royalties or intellectual project from Cervico, Roche, MSD, BMS; J-BB received consulting fees and lecture fees from Amgen, Bayer, Merck Serono, and Servier and lecture fees from Celgene, Roche, and Sanofi.